bioAffinity - חוב לטווח קצר של החברה BIAF

bioAffinity Technologies (BIAF) is implementing advanced non-invasive sputum analysis tests for the early detection of lung cancer. The business relies on stable demand that is independent of economic cycles or seasonality. The team is based on a staff of dedicated molecular biologists and recruited clinical experts. The current metric is 0.00. This chart of stock quotes illustrates the dynamics of the issuer's short-term debt obligations.

This indicator measures the total volume of liabilities with a maturity of up to one year, allowing the investor to assess the risk of insolvency and the efficiency of working capital management. By analyzing short-term debt statistics, one can confirm the financial stability of bioAffinity Technologies (BIAF), whose experienced oncology diagnostics team is successfully scaling its commercial network while maintaining a high level of creditor confidence.